miRNA Biomarker Panel for Lung Disease Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current miRNA biomarkers for lung diseases, such as sarcoidosis, lung cancer, and COPD, suffer from low sensitivity and specificity, and are unable to provide timely diagnosis, with a lack of effective methods for differential diagnosis between these conditions.
Innovation Solution
The use of specific polynucleotides to detect miRNA signatures in blood samples, comprising nucleotide sequences from Set No. 1 to 42 of Figure 15, for diagnosing sarcoidosis, and employing a method involving expression profile determination and comparison to a reference for accurate diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If current miRNA biomarkers are used for diagnosing lung diseases, then the diagnostic process is simplified, but the sensitivity and specificity remain low
Solution Approach 1:
The patent combines multiple miRNA biomarkers into a single diagnostic panel that simultaneously measures several miRNAs (including miR-21, miR-155, miR-146a, and others) to achieve both operational simplicity and high diagnostic precision. This merging approach allows the diagnostic system to maintain ease of use while overcoming the low sensitivity and specificity of individual miRNA markers.
2Device complexity
If single miRNA markers are used for diagnosis, then the diagnostic method is simple, but the accuracy and timeliness of diagnosis are insufficient
Solution Approach 1:
The patent creates a composite diagnostic approach by integrating multiple miRNA markers into a unified diagnostic system. This composite strategy combines the diagnostic information from several different miRNAs, each with distinct expression patterns in various lung diseases, thereby achieving high accuracy and timely diagnosis without excessive complexity.
3Ease of operation
If existing miRNA biomarkers are applied, then the diagnostic approach is straightforward, but the ability to differentiate between lung cancer, COPD, and sarcoidosis is insufficient
Solution Approach 1:
The patent applies local quality by assigning specific diagnostic functions to different miRNA markers within the panel. Each miRNA provides localized diagnostic information for specific disease types: certain miRNAs are more indicative of lung cancer, others of COPD, and others of sarcoidosis. This allows the straightforward diagnostic approach to achieve precise differential diagnosis through the differentiated expression patterns of individual markers within the unified panel.
Data Source
Figure 1
Figure 1
Figure 1
AI summary
The present invention relates to single polynucleotides or sets of polynucleotides for detecting single miRNAs or sets of miRNAs for diagnosing and/or prognosing of a lung disease in a biological sample from a patient. Further, the present invention relates to means for diagnosing and/or prognosing of a lung disease comprising said polynucleotides or sets of polynucleotides. Furthermore, the present invention relates to a method for diagnosing and/or prognosing of a lung disease based on the determination of expression profiles of single miRNAs or sets of miRNAs representative for a lung disease. In addition, the present invention relates to a kit for diagnosing and/or prognosing of a lung disease comprising means for determining expression profiles of single miRNAs or sets of miRNAs representative for a lung disease and optionally at least one reference and/or algorithm or mathematical function comprised on at least one data carrier.